1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. CDK

CDK

CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.

There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.

CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of S. pombe (Cdc2), S. cerevisia (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).

CDK Isoform Specific Products:

  • CDK1

  • CDK2

  • CDK3

  • CDK4

  • CDK5

  • CDK6

  • CDK7

  • CDK8

  • CDK9

  • CDK11

  • CDK12

  • CDK13

  • CDK14

  • CDK16

  • CDK19

  • CDC

  • CLK

CDK Related Products (139):

Cat. No. Product Name Effect Purity
  • HY-50767
    Palbociclib Inhibitor 99.96%
    Palbociclib (PD 0332991) is a selective CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib can be used for the treatment of ER-positive and HER2-negative breast cancer.
  • HY-16297
    Abemaciclib methanesulfonate Inhibitor 99.95%
    Abemaciclib methanesulfonate (LY2835219 methanesulfonate) is a selective CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively.
  • HY-50767A
    Palbociclib hydrochloride Inhibitor 99.94%
    Palbociclib hydrochloride is a highly selective CDK4/6 inhibitor with IC50s of 11 nM and 16 nM, respectively.
  • HY-15777
    Ribociclib Inhibitor 99.85%
    Ribociclib (LEE01) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.
  • HY-103618
    THZ531 Inhibitor 99.86%
    THZ531 is a covalent inhibitor of both CDK12 and CDK13 with IC50s of 158 nM and 69 nM, respectively.
  • HY-112296
    T025 Inhibitor 98.01%
    T025 is an orally available and highly potent Cdc2-like kinase (CLK) inhibitor with Kds of 4.8, 0.096, 6.5, and 0.61 nM for CLK1, CLK2, CLK3, and CLK4, respectively.
  • HY-120350
    BI-1347 Inhibitor 99.83%
    BI-1347 is a potent CDK8 inhibitor extracted from patent WO2017202719A1, product I-003, has an IC50 of 1.1 nM.
  • HY-123937
    THAL-SNS-032 Inhibitor 99.16%
    THAL-SNS-032 is a selective CDK9 degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN).
  • HY-10492
    Dinaciclib Inhibitor 99.73%
    Dinaciclib is a potent inhibitor of CDK, with IC50s of 1, 1, 3, and 4 nM for CDK2, CDK5, CDK1, and CDK9, respectively.
  • HY-30237
    Seliciclib Inhibitor 99.94%
    Seliciclib (Roscovitine) is an orally bioavailable and selective CDKs inhibitor with IC50s of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively.
  • HY-80013
    THZ1 Inhibitor 98.82%
    THZ1 is a selective and potent covalent CDK7 inhibitor with an IC50 of 3.2 nM.
  • HY-10005
    Flavopiridol Inhibitor 99.72%
    Flavopiridol is a broad spectrum and competitive inhibitor of CDKs, inhibiting CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively.
  • HY-12529
    Ro-3306 Inhibitor
    Ro-3306 is a potent and selective inhibitor of CDK1, with Kis of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin B1 and CDK2/cyclin E, respectively.
  • HY-12214A
    NVP-2 Inhibitor 99.29%
    NVP-2 is a CDK9 inhibitor with an IC50 of 0.5 nM.
  • HY-A0065
    Palbociclib isethionate Inhibitor 99.96%
    Palbociclib isethionate is a highly selective inhibitor of CDK4/6 with IC50s of 11 nM/16 nM, respectively. 
  • HY-101212
    CYC065 Inhibitor 99.78%
    CYC065 is a second-generation, orally available ATP-competitive inhibitor of CDK2/CDK 9 kinases.
  • HY-16297A
    Abemaciclib Inhibitor 99.69%
    Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.
  • HY-80013A
    THZ1 Hydrochloride Inhibitor 98.70%
    THZ1 Hydrochloride is a selective and potent CDK7 inhibitor with an IC50 of 3.2 nM.
  • HY-112088
    AZD4573 Inhibitor 99.80%
    AZD4573 is a CDK9 inhibitor with an IC50 of <3 nM extracted from patent US 20160376287 A1, example 14.
  • HY-12871
    Atuveciclib Racemate Inhibitor 98.48%
    Atuveciclib Racemate (BAY-1143572 Racemate) is the racemate mixture of Atuveciclib. Atuveciclib is a potent and highly selective, oral P-TEFb/CDK9 inhibitor which supresses CDK9/CycT1 with an IC50 of 13 nM.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.